Merck-Moderna mRNA Vaccine Stops Melanoma Return in Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck/MSD and Moderna said their personalized vaccine Intismeran, combined with Keytruda, significantly extended cancer-free time and reduced the risk of melanoma spreading in a Phase 3 trial of over 1,000 patients with stage II-IV high-risk melanoma who had undergone surgery.
- The mRNA-based jab is built by surgically removing a tumor sample, sequencing its DNA, and creating a patient-specific vaccine that instructs the immune system to hunt any remaining cancer cells — the same mRNA platform used in some Covid-19 vaccines.
- Moderna CEO Stephane Bancel called the findings a "pivotal moment" in cancer research, and shares in both Moderna and Merck surged after the announcement.
- Cancer experts urged caution: the results are interim, not yet peer-reviewed or fully released, with full Phase 3 data due for presentation at a medical conference in October.
- Even if the trial succeeds, the treatment must clear regulator approval and a separate NHS sign-off before reaching UK patients, and the two companies are already testing similar personalized vaccines against lung, bladder and kidney cancers.
- NHS England's Prof Peter Johnson said the result was a "very important advance" and the NHS is preparing to bring this type of treatment to patients; University of Oxford's Dr Lennard Lee called it "proof of principle that personalised cancer vaccines work."
Why it matters: The melanoma readout is proof of principle for the personalized cancer-vaccine concept, with Merck and Moderna testing the same mRNA platform against lung, bladder and kidney cancers — so melanoma is just the first frontier. Patients won't benefit soon: interim data isn't peer-reviewed, regulators must still approve the jab, and the NHS would run its own sign-off, with full Phase 3 results not presented until October.
Ask SkimNews
